Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer
A Prospective Phase II Study of Attenuated S-1 and Oxaliplatin(Attenuated SOX) as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Treatment scheme
- S-1 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours
Each cycle is repeated every 3 weeks
Response evaluation will be performed every 2 cycles
Repeated cycles of treatment will be given for this study unless there is confirmed disease progression or unacceptable toxicity.
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age : more than 70 to 80 and ECOG PS 0-2
- Age : more than 65 to less than 70 and ECOG PS 2
- Histological or pathologically confirmed adenocarinoma
- Relapsed or metastatic adenocarcinoma of stomach
- No previous chemotherapy except adjuvant chemotherapy completed at least 12 months before enrollment
- At least more than one measurable lesion on RECIST criteria
- No radiation history for the target lesion
- An estimated life expectancy of more than 3 months
- Ability for adequate oral intake
- Adequate BM function: defined as WBC≥4000/μL, ANC ≥1500/μL, PLT≥100,000/μL.
- Adequate renal function: defined as Creatinine <1.5mg/dL.
- Adequate hepatic function: defined as total bilirubin < 2.0mg/dL, SGOT/SGPT < normal x 3.
- Written informed consent
Exclusion Criteria:
- Symptomatic brain metastasis or meningeal metastasis.
- Double primary cancer
- Medical history of other cancer within 5 years
- G-I bleeding or intestinal obstruction (other condition that can't have the oral intake)
- Hypersensitivity to the 5-FU or oxaliplatin
- Active infectious disease that need to treat systemically
- Serious medical or psychologic condition: newly developed AMI ( within 6Ms)…
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate response rate of attenuated SOX as first-line chemotherapy in elderly patients with relapsed or metastatic AGC
Time Frame: every 2 cycles
|
every 2 cycles
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
To evaluate progression free survival, overall survival, and toxicities of aSOX-regimen
Time Frame: every 2 months
|
every 2 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Sang-Cheol Lee, M.D., Soonchunhyang University Hospital
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ANTICIPATED)
Primary Completion
Study Completion (ANTICIPATED)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SCH-HO-GC-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.